skip to content

Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID)

 
Read more at: HKJCGHI hosts plaque-unveiling ceremony to launch headquarters and a joint lab with Cambridge to drive global health innovation

HKJCGHI hosts plaque-unveiling ceremony to launch headquarters and a joint lab with Cambridge to drive global health innovation

20 October 2025

The Hong Kong Jockey Club Global Health Institute (HKJCGHI) proudly celebrated a significant milestone today (17 October) with the unveiling of its headquarters and a cutting-edge joint laboratory with the University of Cambridge (UCAM) located at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed). This...


Read more at: New study charts the cellular landscape of iron control
Photo of Anthony Martinelli and James Nathan

New study charts the cellular landscape of iron control

6 October 2025

Work led by Anthony Martinelli in James Nathan ’s group (CITIID, Medicine), now published in Science Advances , provides the first comprehensive map of the critical genes that regulate iron within our cells. Iron is a classic double-edged sword: essential for life, yet toxic in excess. This new map of the cell’s iron-...


Read more at: Connecting minds, shaping frontiers: Department of Medicine Annual Research Day 2025
Picture of audiences at the Robinson College

Connecting minds, shaping frontiers: Department of Medicine Annual Research Day 2025

22 September 2025

Our Annual Research Day is the largest forum for presenting research by faculty, staff, and trainees in the Department of Medicine.


Read more at: Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial

Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial

4 August 2025

Recent publication in Scientific Reports from a large collaborative effort led by Professor Ravi Gupta showing that fractional doses of COVID-19 vaccine elicit comparable neutralising antibody responses to variants of concern as full dose vaccine in the west African setting.


Read more at: Cold sore virus immediately reshapes our genome to boost its growth

Cold sore virus immediately reshapes our genome to boost its growth

15 July 2025

Benjamin Krishna commented in New Scientist on new research that has identified an experimental cancer drug that could help treat the HSV-1 virus in people with severe cold sores or those who have a suppressed immune system.


Read more at: New study reveals key enzyme to control cellular energy production and immune function
Colorized scanning electron micrograph of a T lymphocyte  (also known as a T cell) (blue). Credit: NIAID

New study reveals key enzyme to control cellular energy production and immune function

15 July 2025

Uncovering ABHD11 as a key metabolic regulator could lead to new treatments for cancer, autoimmune diseases, and metabolic disorders. A new study led by researchers at the University of Cambridge and the Karolinska Institute has identified a key enzyme that controls how cells generate energy and mount immune responses. The...


Read more at: Professor Gordon Dougan recognised in King’s Birthday Honours 2025
Professor Dougan headshot

Professor Gordon Dougan recognised in King’s Birthday Honours 2025

16 June 2025


Read more at: Ravi Gupta appointed as Hong Kong Jockey Club Chair in Global Health and Co-Director of the Global Health Institute, Hong Kong
GHI scientific meeting

Ravi Gupta appointed as Hong Kong Jockey Club Chair in Global Health and Co-Director of the Global Health Institute, Hong Kong

21 May 2025


Read more at: Listening to Your Gut: a cross-disciplinary talk at the Cambridge Festival 2025
Speaker panel at the Listening to Your Gut

Listening to Your Gut: a cross-disciplinary talk at the Cambridge Festival 2025

9 April 2025

"What happens in the gut doesn't stay in the gut," said Dr Virginia Pedicord during the talk 'Listening to Your Gut' at the Cambridge Festival 2025.


Read more at: Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing

Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing

18 March 2025

Maxion Therapeutics , a Cambridge-based biotechnology company co-founded by Dr. John McCafferty , Affiliate Professor at the Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID) and the Department of Medicine, University of Cambridge, has successfully raised $72 million (£58 million) in an...